These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 23209702)

  • 1. A functional variant in the MTOR promoter modulates its expression and is associated with renal cell cancer risk.
    Cao Q; Ju X; Li P; Meng X; Shao P; Cai H; Wang M; Zhang Z; Qin C; Yin C
    PLoS One; 2012; 7(11):e50302. PubMed ID: 23209702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of genetic polymorphisms in pTEN/AKT/mTOR signaling pathway genes with cancer risk: A meta-analysis in Asian population.
    Zhang Z; Chen Q; Zhang J; Wang Y; Hu X; Yin S; He M; Guan S; Qin W; Xiao Q; Zhao H; Yao W; Wu H; Wei M
    Sci Rep; 2017 Dec; 7(1):17844. PubMed ID: 29259266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional promoter rs2295080 T>G variant in MTOR gene is associated with risk of colorectal cancer in a Chinese population.
    Xu M; Gao Y; Yu T; Wang J; Cheng L; Cheng L; Cheng D; Zhu B
    Biomed Pharmacother; 2015 Mar; 70():28-32. PubMed ID: 25776475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic variations in a PTEN/AKT/mTOR axis and prostate cancer risk in a Chinese population.
    Chen J; Shao P; Cao Q; Li P; Li J; Cai H; Zhu J; Wang M; Zhang Z; Qin C; Yin C
    PLoS One; 2012; 7(7):e40817. PubMed ID: 22815832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A polymorphism (rs2295080) in mTOR promoter region and its association with gastric cancer in a Chinese population.
    Xu M; Tao G; Kang M; Gao Y; Zhu H; Gong W; Wang M; Wu D; Zhang Z; Zhao Q
    PLoS One; 2013; 8(3):e60080. PubMed ID: 23555892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The associations of hub gene polymorphisms in PI3K/AKT/mTOR pathway and Schistosomiasis Japonica infection and hepatic fibrosis.
    Xiao Q; Yu H; Zhu X
    Infect Genet Evol; 2020 Nov; 85():104423. PubMed ID: 32554084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Energy balance, polymorphisms in the mTOR pathway, and renal cell carcinoma risk.
    Shu X; Lin J; Wood CG; Tannir NM; Wu X
    J Natl Cancer Inst; 2013 Mar; 105(6):424-32. PubMed ID: 23378641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The genetic variants in the PTEN/PI3K/AKT pathway predict susceptibility and CE(A)F chemotherapy response to breast cancer and clinical outcomes.
    Li X; Zhang R; Liu Z; Li S; Xu H
    Oncotarget; 2017 Mar; 8(12):20252-20265. PubMed ID: 28423632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy.
    Hildebrandt MA; Yang H; Hung MC; Izzo JG; Huang M; Lin J; Ajani JA; Wu X
    J Clin Oncol; 2009 Feb; 27(6):857-71. PubMed ID: 19164214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations between single-nucleotide polymorphisms in the PI3K-PTEN-AKT-mTOR pathway and increased risk of brain metastasis in patients with non-small cell lung cancer.
    Li Q; Yang J; Yu Q; Wu H; Liu B; Xiong H; Hu G; Zhao J; Yuan X; Liao Z
    Clin Cancer Res; 2013 Nov; 19(22):6252-60. PubMed ID: 24077347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic variants in the mTOR pathway with renal cancer risk and subtypes in East Indian population.
    Malakar S; Chatterjee S; Das M; Pal DK
    Urologia; 2024 May; 91(2):270-275. PubMed ID: 38205940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variants in PI3K/Akt/mTOR pathway genes contribute to gastric cancer risk.
    Ge Y; Liu H; Qiu X; Ma G; Wang H; Du M; Wang M; Zhao Q; Tao G; Chu H; Zhang Z
    Gene; 2018 Sep; 670():130-135. PubMed ID: 29802999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variants in angiogenesis-related genes and the risk of clear cell renal cell carcinoma.
    Qin C; Chen J; Li J; Ju X; Zhang S; Cao Q; Han Z; Li P; Shao P; Wang M; Zhang Z; Gu M; Zhang W; Yin C
    Mutagenesis; 2014 Nov; 29(6):419-25. PubMed ID: 25239121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the MTOR and AKT1 genes polymorphisms on papillary thyroid cancer development.
    Maruei-Milan R; Saravani M; Heidari Z; Asadi-Tarani M; Salimi S
    IUBMB Life; 2020 Dec; 72(12):2601-2610. PubMed ID: 33107190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miRNA‑205‑5p functions as a tumor suppressor by negatively regulating VEGFA and PI3K/Akt/mTOR signaling in renal carcinoma cells.
    Huang J; Wang X; Wen G; Ren Y
    Oncol Rep; 2019 Nov; 42(5):1677-1688. PubMed ID: 31545453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.
    Wang LE; Ma H; Hale KS; Yin M; Meyer LA; Liu H; Li J; Lu KH; Hennessy BT; Li X; Spitz MR; Wei Q; Mills GB
    J Cancer Res Clin Oncol; 2012 Mar; 138(3):377-85. PubMed ID: 22146979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
    Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
    Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional promoter -31G>C variant in survivin gene is associated with risk and progression of renal cell cancer in a Chinese population.
    Qin C; Cao Q; Li P; Ju X; Wang M; Chen J; Wu Y; Meng X; Zhu J; Zhang Z; Lu Q; Yin C
    PLoS One; 2012; 7(1):e28829. PubMed ID: 22295057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations of Genetic Polymorphisms of mTOR rs2295080 T/G and rs1883965 G/A with Susceptibility of Urinary System Cancers.
    Min Z; Mi Y; Lv Z; Sun Y; Tang B; Wu H; Zhang Z; Pan H; Zhang Y; Lu C; Zuo L; Zhang L
    Dis Markers; 2022; 2022():1720851. PubMed ID: 35082928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy.
    Nishikawa M; Miyake H; Harada K; Fujisawa M
    Urol Oncol; 2014 Jan; 32(1):49.e15-21. PubMed ID: 24239474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.